Actively Enrolling Clinical Trials

Please call 1-800-354-9527 (Virginia Mason Hospital Operator). Ask for the coordinator listed under the trial(s) you are interested in participating and/or obtaining more information.

Heart Institute

(Cardiology)

Prospective Clinical Study of the Guidant Microwave Ablation System for the Treatment of PAF in the MIS Procedure

Principal Investigator: Mark Hill, MD

Coordinator: Jill Zeller, RN

Email: Jill.zeller@vmmc.org

Cancer

(Oncology)

SPIRITT - Q2W FOLFIRI Regimen Plus Panitumumab or a Q2W FOLFIRI Regimen Plus Bevacizumab for 2nd-Line mCRC

Principal Investigator: Andrew Jacobs, MD

Coordinator: Louise Soltow

Email: louise.soltow@vmmc.org

A Study Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Principal Investigator: Andrew Jacobs, MD

Coordinator: Louise Soltow

Email: louise.soltow@vmmc.org

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

Principal Investigator: Thomas Malpass, MD

Coordinator: Marisa Cody

Email: Marisa.cody@vmmc.org

A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)

Principal Investigator: Henry Otero, MD

Coordinator: Louise Soltow

Email: louise.soltow@vmmc.org

First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy

Principal Investigator: Jacqueline Vuky, MD

Coordinator: Louise Soltow

Email: louise.soltow@vmmc.org

Digestive Disease Institute (DDI)

(Gastroenterology)

A Study of the WallFlex&trade Biliary Fully-Covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction

Principal Investigator: Richard Kozarek, MD

Coordinator: Nicoline Lomah

Email: Nicoline.lomah@vmmc.org

Efficacy and Safety of DNK333 in Women With Diarrhea-Predominant Irritable Bowel Syndrome

Principal Investigator: Otto Lin, MD

Coordinator: Nicoline Lomah

Email: Nicoline.lomah@vmmc.org

Neurology

Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-Remitting Multiple Sclerosis

Principal Investigator: Mariko Kita, MD

Coordinator: Leslie Stevens

Email: leslie.stevens@vmmc.org

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

Principal Investigator: Lynne Taylor, MD

Coordinator: Jill Zeller, RN

Email: Jill.zeller@vmmc.org

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

Principal Investigator: Lynne Taylor, MD

Coordinator: Jill Zeller, RN

Email: Jill.zeller@vmmc.org

Urology

cG250 Monoclonal Antibody Vs Placebo for Renal Cell Carcinoma

Principal investigator: John Corman, MD

Coordinator: Kathryn Dahl

Email: Kathryn.dahl@vmmc.org

Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy

Principal Investigator: John Corman, MD

Coordinator: Erin Odom

Email: erin.odom@vmmc.org

Type 1 Diabetes

hOKT3gamma1 (Ala-Ala) in People Recently Diagnosed With Type 1 Diabetes

Condition: Diabetes Mellitus, Type 1

Principal investigator: Carla Greenbaum, MD

Recruitment Coordinator: Christine Webber

Email: diabetes@benaroyaresearch.org

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Condition: Diabetes Mellitus, Type 1

Principal investigator: Carla Greenbaum, MD

Recruitment Coordinator: Christine Webber

Email: diabetes@benaroyaresearch.org

Natural History Study of the Development of Type 1 Diabetes Condition: Diabetes Mellitus, Type 1

Principal investigator: Carla Greenbaum, MD

Recruitment Coordinator: Christine Webber

Email: diabetes@benaroyaresearch.org